Aon plc's Managed Care Services Team has completed an independent review of DarioHealth Corp.'s AI-powered chronic condition management services, concluding that the evidence supports estimated annual healthcare cost reductions of 2.5% to 7.2% across a covered population. For a representative population of 20,000 covered lives, that translates to approximately $3.8 million to $10.8 million in annual savings. The findings, announced by DarioHealth (NASDAQ: DRIO), could strengthen the company's position in the competitive digital health market, where employers and health plans increasingly demand proven financial returns before adopting new chronic care solutions.
The Aon review evaluated 17 studies spanning cardiometabolic, musculoskeletal, and behavioral health conditions. These included both independently conducted and company-sponsored research. Aon found consistent reported improvements across clinical, behavioral, healthcare utilization, and cost measures, concluding that the evidence supports an association between DarioHealth services and meaningful clinical and financial outcomes. Notably, Aon estimated that management of multiple conditions and access to physicians—factors excluded from the initial calculations—could contribute an additional 1.6 to 2.8 percentage points in savings. This suggests that DarioHealth's integrated platform may deliver even greater value when fully utilized.
The implications for DarioHealth are significant. In a healthcare landscape where payers and employers are scrutinizing every dollar, independent validation from a respected firm like Aon can serve as a powerful differentiator. It provides third-party credibility that DarioHealth can use to accelerate adoption among health plans, health systems, and employers. The estimated savings range also offers potential customers a tangible framework for evaluating return on investment, which is often a barrier to entry for digital health solutions.
However, Aon did not independently verify the underlying data or audit the studies, and its findings do not guarantee future savings or outcomes for individual customers. This caveat is important for investors and prospective clients to consider. While the review is supportive, it is not an endorsement of guaranteed results. DarioHealth's ability to replicate these savings in real-world settings will ultimately determine its long-term success.
DarioHealth's platform combines connected devices, personalized member engagement, AI-driven insights, and provider-backed clinical care. Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, the company's AI personalizes care at the individual member level. By addressing multiple chronic conditions through a single solution, DarioHealth aims to simplify care delivery and reduce costs. The full press release can be viewed at https://ibn.fm/IFvLH, and the latest news and updates relating to DRIO are available in the company's newsroom at https://ibn.fm/DRIO.
The announcement was distributed through BioMedWire, one of more than 75 brands within the Dynamic Brand Portfolio at IBN. BioMedWire provides wire solutions via InvestorWire, including editorial syndication to 5,000+ outlets and social media distribution, helping companies reach investors and other audiences. For more information, visit https://www.BioMedWire.com/Disclaimer.
